The GLP-1 peptide drug exenatide not only lowered brain pressure in IIH patients but significantly improved fluid intelligence, processing speed, and memory over 12 weeks — unlike current treatments that often worsen cognition.
38.4 → 52.9 fluid intelligenceexenatide brought fluid intelligence from significantly impaired to population average in IIH patients over just 12 weeks (p=0.0005)
What the researchers found
In women with idiopathic intracranial hypertension (IIH), exenatide (a GLP-1 receptor agonist) did not compromise cognition over 12 weeks compared to placebo. Patients treated with exenatide showed significant improvements in fluid intelligence (T-score 38.4→52.9, p=0.0005), processing speed (43.7→58.4, p=0.0058), and episodic memory (49.4→62.1, p=0.0315). Baseline cognitive impairment was confirmed in fluid intelligence, attention, and executive function (all T-scores well below population mean of 50).
Why it matters
IIH patients suffer cognitive impairment from raised intracranial pressure, and current medications often worsen thinking problems as a side effect. Exenatide both lowers intracranial pressure and appears to improve rather than harm cognition — a potential game-changer for IIH treatment and another example of GLP-1 peptide drugs showing unexpected brain benefits.
The numbers in context
n=15 (7 exenatide, 8 placebo) · 12 weeks · fluid intelligence improved 38.4→52.9 (p=0.0005) · processing speed 43.7→58.4 (p=0.0058) · episodic memory 49.4→62.1 (p=0.0315) · T-score 50 = population mean
How the study worked
Exploratory analysis from the IIH:Pressure randomized trial. 15 women with IIH and implanted telemetric ICP monitors were randomized to exenatide (n=7) or placebo (n=8) for 12 weeks. Cognition was assessed at baseline and 12 weeks using the NIH Toolbox Cognitive Battery, measuring fluid intelligence, attention, executive function, processing speed, and episodic memory.
Who was studied
15 women with idiopathic intracranial hypertension and implanted telemetric ICP monitors
What this study cannot tell us
Very small sample (n=15, only 7 on exenatide). Exploratory analysis — not the primary endpoint of the trial. No correction for multiple comparisons. All female participants. Practice effects from repeat cognitive testing could contribute to improvements. Cannot determine if cognitive improvements were from direct brain effects of exenatide or secondary to ICP reduction.
How to read the evidence
This is an exploratory analysis from a randomized placebo-controlled trial, which is a strong design. However, the very small sample size (n=15), exploratory nature, and lack of multiple comparison correction mean these findings are hypothesis-generating rather than definitive. Larger confirmatory trials are needed.
When this study was published
Published in 2024, this study is part of ongoing investigation into GLP-1 receptor agonists for IIH and broader neurological applications — one of the most exciting emerging areas in peptide therapeutics.
The bigger picture
GLP-1 receptor agonists continue to surprise researchers with benefits far beyond diabetes. Exenatide is already being studied for Parkinson's disease and Alzheimer's, and this study adds IIH-related cognitive impairment to the list. The finding that a GLP-1 peptide can both lower intracranial pressure and improve cognition in a neurological condition highlights the brain-wide effects of this peptide pathway and its therapeutic potential for neurodegenerative and neurological conditions.
Questions still open
- Were the cognitive improvements driven by exenatide's direct neuroprotective effects or indirectly by reducing intracranial pressure?
- Would longer treatment with exenatide produce sustained or even greater cognitive gains in IIH patients?
- Could other GLP-1 agonists like semaglutide show similar cognitive benefits in IIH, potentially with greater potency?
Common questions
What is idiopathic intracranial hypertension (IIH)?
How does a diabetes drug lower brain pressure?
Read the original research
Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
Eye (London, England), 38(7), 1374-1379
Citation
Grech, Olivia; Mitchell, James L; Lyons, Hannah S; Yiangou, Andreas; Thaller, Mark; Tsermoulas, Georgios; Brock, Kristian; Mollan, Susan P; Sinclair, Alexandra J. (2024). Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.. Eye (London, England), 38(7), 1374-1379. https://doi.org/10.1038/s41433-023-02908-y